The Phase Zero Approach- There is a "translational valley of death": The success rate for a new target identified to reach the next step in the drug discovery process is undeniable low and wrought with failure. This is because many of the pre-clinical models to date do not accurately recapitulate the human system, and assessment of efficacy typically waits until Phase III clinical trials.
- HUMANOID is dedicated to build and validate pre-clinical human healthy and disease models as platforms for research and drug development, and enable early ex vivo testing for toxicity and efficacy.
- With few exceptions, all tissues from human, mouse, embryonic, adult, diseased, normal, iPSCs, can be developed into organoids, and subsequently into disease models with a few network-guided tweaks.
- Our ex vivo models recreate the complexity in vivo by making multi-dimensional organoids [co-culture techniques that capture the 3D of organoid tissues + microbiome + immune or non-immune cells]
- In powerful synergy with iNetMed's precise AI-assisted target discovery, HUMANOID can build personalized models with patient tissue; together, they enable "precisionalized" medicine.
- HUMANOID collaborates with an extensive network of clinicians, industry collaborators and basic scientists, both on and off campus.
- HUMANOID's services include enabling the research community to access and experiment with human primary cells, organoids, enteroid derived monolayers, derivatives of organoids, support sponsored research projects, provide consultation, offer formal and informal education on organoid research and more.
- HUMANOID is located in the George Palade Laboratories (GPL) for Cellular and Molecular Medicine [Room 238].
|